CULP INC (CULP)

US2302151053 - Common Stock

5.78  +0.27 (+4.9%)

Fundamental Rating

2

Taking everything into account, CULP scores 2 out of 10 in our fundamental rating. CULP was compared to 50 industry peers in the Textiles, Apparel & Luxury Goods industry. Both the profitability and financial health of CULP have multiple concerns. CULP does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

CULP had negative earnings in the past year.
In the past year CULP has reported a negative cash flow from operations.
In the past 5 years CULP reported 4 times negative net income.
In multiple years CULP reported negative operating cash flow during the last 5 years.

1.2 Ratios

The Return On Assets of CULP (-16.25%) is worse than 84.00% of its industry peers.
CULP's Return On Equity of -32.94% is on the low side compared to the rest of the industry. CULP is outperformed by 74.00% of its industry peers.
Industry RankSector Rank
ROA -16.25%
ROE -32.94%
ROIC N/A
ROA(3y)-10.99%
ROA(5y)-8.96%
ROE(3y)-18.73%
ROE(5y)-15.17%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 11.19%, CULP is doing worse than 96.00% of the companies in the same industry.
In the last couple of years the Gross Margin of CULP has declined.
CULP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 11.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.3%
GM growth 5Y-6.23%

3

2. Health

2.1 Basic Checks

CULP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CULP has more shares outstanding
Compared to 5 years ago, CULP has more shares outstanding
There is no outstanding debt for CULP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CULP has an Altman-Z score of 2.62. This is not the best score and indicates that CULP is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.62, CULP perfoms like the industry average, outperforming 48.00% of the companies in the same industry.
CULP has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
CULP has a better Debt to Equity ratio (0.06) than 70.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 2.62
ROIC/WACCN/A
WACC9.16%

2.3 Liquidity

CULP has a Current Ratio of 1.79. This is a normal value and indicates that CULP is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.79, CULP is not doing good in the industry: 64.00% of the companies in the same industry are doing better.
A Quick Ratio of 0.86 indicates that CULP may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.86, CULP is doing worse than 72.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 0.86

3

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.65% over the past year.
CULP shows a decrease in Revenue. In the last year, the revenue decreased by -3.13%.
CULP shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.34% yearly.
EPS 1Y (TTM)0.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.63%
Revenue 1Y (TTM)-3.13%
Revenue growth 3Y-9.07%
Revenue growth 5Y-4.34%
Sales Q2Q%-5.2%

3.2 Future

Based on estimates for the next years, CULP will show a very strong growth in Earnings Per Share. The EPS will grow by 37.01% on average per year.
CULP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.45% yearly.
EPS Next Y52.34%
EPS Next 2Y51.19%
EPS Next 3Y37.01%
EPS Next 5YN/A
Revenue Next Year-0.13%
Revenue Next 2Y4.87%
Revenue Next 3Y6.45%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

3

4. Valuation

4.1 Price/Earnings Ratio

CULP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 18.89, the valuation of CULP can be described as rather expensive.
CULP's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.99, CULP is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 18.89

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

CULP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CULP's earnings are expected to grow with 37.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.19%
EPS Next 3Y37.01%

0

5. Dividend

5.1 Amount

No dividends for CULP!.
Industry RankSector Rank
Dividend Yield N/A

CULP INC

NYSE:CULP (12/24/2024, 8:05:25 PM)

5.78

+0.27 (+4.9%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryTextiles, Apparel & Luxury Goods
Earnings (Last)12-04 2024-12-04/amc
Earnings (Next)N/A N/A
Inst Owners64.39%
Inst Owner Change0.87%
Ins Owners7.14%
Ins Owner Change8.45%
Market Cap72.60M
Analysts82.86
Price Target8.16 (41.18%)
Short Float %0.16%
Short Ratio1.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.55%
Min EPS beat(2)-7.29%
Max EPS beat(2)16.38%
EPS beat(4)2
Avg EPS beat(4)-2.51%
Min EPS beat(4)-34.16%
Max EPS beat(4)16.38%
EPS beat(8)5
Avg EPS beat(8)6.11%
EPS beat(12)6
Avg EPS beat(12)-13.51%
EPS beat(16)9
Avg EPS beat(16)-4.27%
Revenue beat(2)1
Avg Revenue beat(2)-0.66%
Min Revenue beat(2)-5.9%
Max Revenue beat(2)4.58%
Revenue beat(4)1
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.9%
Max Revenue beat(4)4.58%
Revenue beat(8)2
Avg Revenue beat(8)-1.21%
Revenue beat(12)5
Avg Revenue beat(12)0.53%
Revenue beat(16)8
Avg Revenue beat(16)2%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)500%
EPS NQ rev (3m)500%
EPS NY rev (1m)39.76%
EPS NY rev (3m)48.98%
Revenue NQ rev (1m)-3.88%
Revenue NQ rev (3m)-3.88%
Revenue NY rev (1m)-4.39%
Revenue NY rev (3m)-0.79%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 18.89
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)0.31
Fwd EY5.29%
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS17.69
BVpS5.07
TBVpS4.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.25%
ROE -32.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 11.19%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-8.96%
ROE(3y)-18.73%
ROE(5y)-15.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.3%
GM growth 5Y-6.23%
F-Score4
Asset Turnover1.72
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.18%
Cap/Sales 1.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.79
Quick Ratio 0.86
Altman-Z 2.62
F-Score4
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)52.71%
Cap/Depr(5y)60.65%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.63%
EPS Next Y52.34%
EPS Next 2Y51.19%
EPS Next 3Y37.01%
EPS Next 5YN/A
Revenue 1Y (TTM)-3.13%
Revenue growth 3Y-9.07%
Revenue growth 5Y-4.34%
Sales Q2Q%-5.2%
Revenue Next Year-0.13%
Revenue Next 2Y4.87%
Revenue Next 3Y6.45%
Revenue Next 5YN/A
EBIT growth 1Y20.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year228.39%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.84%
OCF growth 3YN/A
OCF growth 5YN/A